|
Group of inventions relates to biotechnology. The strain Bifidobacterium lactis CNCM I-3446 is applicable in preparing a probiotic composition for stimulating development of initial bifidogenic intestinal microbiota in the children delivered by caesarean section. The strain may be used in preparing the probiotic composition for reducing a risk of further development of allergy, as well as for preventing or treating diarrhoea in these children. |
|
|
Pharmaceutical composition for treatment and prophylaxis of bacterial infection Pharmaceutical composition includes bacteriophages obtained by cultivation on nutritional medium containing glucose, sodium chloride, twice-substituted sodium phosphate, liquid autolysed yeast and clean water in the specified ratio, and dried and having a filler without lyophilisation, in the form of pills with a gastral-resistant coating. |
|
 |
Invention refers to pharmaceutical industry, namely a bioregulatory complex possessing regenerative action. The bioregulatory complex possessing regenerative action prepared of gills of post-settlement Atlantic salmon (Salmo salar L.) activated for a prolonged life cycle with symbiotic pearl shell (Margaritifera margaritifera) alevins, containing peptides and oligosaccharides with certain physicochemical characteristics. A method for preparing a bioregulatory complex consisting the fact that the gills are prepared in the Atlantic salmon fished out after the settlement and placed into water or ethanol; the prepared gill extract is filtered; monoatomic aliphatic alcohol is added to the filtrate that is kept to deposit any foreign matters; the deposition is filtered off; the filtrate is evaporated dry, dissolved in water and cleaned in the specific environment. A method of treating early cataract. |
|
Method of treating patients with hepatic cirrhosis Invention refers to medicine, namely hepatology, and may be used for treating patients with hepatic cirrhosis. That is ensured by prescribing Essentiale Forte N as a hepatoprotective agent, detoxification agents, enzymes, diuretics, hemostatic preparations, vitamins B1, B6, C. The probiotic Linex is additionally taken. If observing Child Pugh A and B hepatic cirrhosis, a dosage is 2 capsules 3 times a day. In Child Pugh A disease, the length of the treatment is 6 weeks, while Child Pugh B requires 7 weeks of the treatment. The stage of Child Pugh C hepatic cirrhosis provides taking 3 capsules 3 times a day. The length of the treatment makes 8-9 weeks. |
|
 |
Method of treating spasticity accompanied by improved consciousness in patients in vegetative state Invention refers to medicine, namely to neurology, and may be used for treating spasticity accompanied by improved consciousness in the patients in the vegetative state. That is ensured by administering Xeomin (botulinumtoxinA free from complexing proteins) into the spastic muscles of all the extremities and related body segments regardless of the contractions in total dose of 400-1300 units. The dose shall not exceed 24 unit/kg of body weight in 1-3 stages. The stages follow at least every 3 days. Every 1-day stage involves administering 5-50 units in each accessible muscle or muscle group with the maximum tone in max. total dose 500 units dissolved in 12.5 unit/ml. The injections are distributed uniformly along the area without electromyography. The following courses are similar if observing spasticity and/or if clinically reasonable. The length of one course is up to 3 weeks. |
|
Using actinomycete lysate for preparing external nail care products Invention refers to pharmaceutical industry, namely to using actynomycete lysate for preparing external nail care products. Using actynomycete lysate of the strains Actinomyces R/3.88, L/1.89 or a mixture thereof for preparing external nail care products. A method for improving the appearance of the nails. |
|
 |
Invention refers to pharmaceutics, namely to the application of a probiotic of the species Lactobacillus rhamnosus in preparing a composition for normalising a patient's pathological lipid profile, wherein the above profile comprises lysophospholipid and/or ceramide sphingolipid. A method for normalising the patient's pathological lipid profile by administering the probiotic of the species Lactobacillus rhamnosus in an amount sufficient to achieve the desired effect, into the patient. |
|
Method for preparing bacterial preparation for preventing bovine postpartum endometritis Invention relates to veterinary science. A method for preparing a bacterial preparation for preventing bovine postpartum endometritis consisting in the fact that preparing involves making a dry nutrient broth for microorganism culture (DNB) according to the package insert; the prepared broth is added with 3% starch pre-dissolved in a small amount of the cooled broth, and then mixed with the rest DNB; the broth is brought to the boiling point, boiled to produce a homogenous transparent mass; then the medium is added with 0.125% NaCl and 2% glucose to pH 6-7, then a phosphate buffer is added: one-substituted 0.8% potassium KH2PO4 and 0.18% two-substituted potassium or sodium K2HPO4 or Na2HPO4; the solution is boiled for 15 minutes, and after cooling, it is added with 0.5% of 80% lactic acid, filtered and autoclaved at 0.5 atm. for 30-40 min; after the solution has been cooled, it is added with the prepared cultures of Lactobacillus fermentum 44/1 and Lactococcus lactis subsp.Lactis 574 no 1 bln. of the microbial cells per 100 ml of the medium in the sterile environment; it is packaged and thermostated for 48 hours at t=37°C. The preparation is tested in 56 cows for the purpose of preventing bovine postpartum endometritis. |
|
|
Method of treating chronic non-specific endometritis Invention refers to medicine, namely gynaecology, and may be used for treating the patients with chronic non-specific endometritis. The method is implemented as follows: a therapeutic agent that is polyvalent complex pyobacteriophage in a dose of 4-7 ml is introduced in a female patient with a completely empty bladder on the 5-7th postmenstrual day. There are 5 procedures of administering pyobacteriophage required. That is followed by the exposure to low-intensity infrared pulse laser at wave length 0.89 mcm, frequency 80 Hz, pulse power 5 Wt; the cutaneous daily 10-minute exposure covers the underbelly. For the 5 of 10 minutes, the exposure covers a projection of the uterus, while for the rest 5 minutes, a projection of the annexes are exposed. The therapeutic course is 10 procedures. Besides, the underbelly exposure is combined with the daily exposure covering a projection of the cubital vessels and the suprasternal notch for 2-3 minutes with the therapeutic course making 10 procedures. The exposure on a projection of the cubital vessels and the suprasternal notch may be both combined with the underbelly exposure, and follow the same. |
|
 |
Method of correcting vaginal dysbiosis in case of metabolic syndrome Invention relates to medicine, namely to gynecology, endocrinology and can be used for correction of vaginal dysbiosis in case of metabolic syndrome. For this purpose complex impact on the organism by correction of body weight by means of no-pharmaceutical and pharmaceutical preparations is performed. Hypocaloric diet with reduced caloric content of 500-600 kcall/day, with reduced content of fats in food up to 20-30% and hypolipidemic direction is administered. Increased physical activity and xenical preparation are also administered for 6 months. Correction of metabolic disorders is carried out by means of preparations possessing antioxidant and membrane-stabilising action daily for 3 months. Recovery of vaginal microflora is performed by means of preliminary sanitation of vaginal biotope with antibacterial preparations for 7 days and immunocorrection for 10 days with further administration of eubiotic preparations for 5-7 days. Correction of vaginal dysbiosis is carried out until amount of opportunistic bacteria decreases and/or content of normal microflora is recovered. |
|
Method for experimental prevention of age-related changes in hepatic tissue Invention refers to medicine and is intended to prevent the age-related changes of hepatic tissue in rats experimentally. What is used is the biologically active additive "Rekicen RD" added to the diet of inbred laboratory rats at the age of two years old. A dose is 2 grams a day for 14 days. |
|
|
Method of treating secondary lactase deficiency Invention refers to medicine, particularly gastroenterology, and may be applied in treating secondary lactase deficiency. For this purpose, with underlying diet and drug-induced therapy, bifiform 1 tablet 2-3 times a day and No-spa 1-2 tablets 3 times a day are additionally administered. The therapeutic course makes 14 days. |
|
|
Method of treating non-alcoholic fatty liver disease Invention relates to medicine, namely to gastroenterology and can be used for treatment of non-alcoholic fatty liver disease. For this purpose administered are metronidasol 250 mg 4 times per day, alpha-normix 200 mg 2 tablets x 2 times per day during 7-10 days.After that, treatment is performed with further administration of bifiform in dose 2 capsules in the morning, probifor in dose 25-30 doses 3 times per day, linex in dose 2 capsules 3 times per day, hylak forte 40-60 drops 3 times per day, sporobacterin 2-4 ml. Duration of intake constitutes 3-4 weeks, also administered is dufalak in dose 5-10 ml per day. Drug therapy of lipid metabolism disorders is performed in dependence of biochemical parameters: in case if ultrasonic signs of steatosis are present and level of transaminases is normal, statins in combination with ezetimibe are administered. If transaminases increase to 3 normal values, essential phospholipids are applied during 3 months. If transaminases increase higher than 3 normal values, ursodeoxycholic acid in dose 15-20 mg/kg is applied; if ultrasonic signs of non-alcoholic steato hepatitis are present and transaminases increase to 3 normal values, statins are administered in dose 20 mg and ursodeoxycholic acid in dose 15-20 mg/kg for 3-6 months. If transaminases increase higher than 3 normal values, treatment is performed with statins in dose 20-40 mg/day and ursodeoxycholic acid in dose 15-20 mg/kg, ezetimibe in dose 10 mg 1 time per day. |
|
|
Therapeutic antimalaria drug based on antimalaria agent and probiotic Invention refers to medicine and biotechnology and represents a therapeutic antimalaria drug containing an antimalaria agent and excipients differing by the fact that it additionally contains a biomass of the Bacillus subtilis probiotic strains in the amount of CFU not less than 1×108 cell/tablet (dose) with the ingredients in the preparation taken in certain proportion, wt %. |
|
 |
Bacterial extract for gastrointestinal or urinary disorders and method for preparing it Invention refers to medicine and pharmacy and represents an immunostimulating extract of one or more bacterial strains Escherichia coli wherein the process of preparing the extract involves lysing one or more bacterial strains at pH more than 12 and processing the extract to separate nucleic acids, and wherein the extract: causes no risk of a prion disease when introduced into the patient, contains less than 100 mcg/ml of nucleic acid, contains chemically modified saccharides, including chemically modified lipopolysaccharide, and contains at least one amino acid which is specified in aspartic acid, glutamic acid, serine, histidine, alanine, arginine, tyrosine, methionine, phenylalanine and lysine; and it is racemised at least by 10%. |
 |
Bacterial extract for respiratory disorders and method for preparing it Invention refers to medicine and pharmacy and represents an immunostimulating extract of one or more bacterial species specified in Moraxella catarrhalis, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes and Streptococcus sanguinis, wherein while preparing said extract one or more bacterial strains are lysed at pH more than 12, and the extract is processed in order to remove nucleic acids; and wherein the extract dies not cause the onset of a prion disease if introduced into a patient wherein the extract contains less than 100 mcg/ml of nucleic acid, wherein the extract contains chemically modified saccharide, including chemically modified lipopolysaccharide, and wherein at least one amino acid which is specified in aspartic acid, glutamic acid, serine, histidine, alanine, arginine, tyrosine, methionine, phenylalanine and lysine, is racemised at least by 10%. |
|
Method of treating patients suffering pulmonary tuberculosis Invention refers to medicine, namely to phthisiology, and may be used for treating patients with pulmonary tuberculosis. That is ensured by conducting the tuberculosis therapy in compliance with the standard schedules and additionally prescribing the probiotic biologically active additive SimBiovital 9.0 g in a single dose every second day with food for two months, and also the Hepel 1 tablet once a day sublingually daily for four months. |
|
|
Group of inventions refers to pharmaceutical industry and medicine and is applicable for producing and using medical immunobiological preparations containing nonpathogenic microorganisms. The compositions (versions) represent a powder containing substances containing nonpathogenic microorganisms dried up in a culture medium specified in a number: Bifidobacterium bacteria and/or Lactobacillus bacteria, and/or species-specific virulent bacteriophages, and/or species-specific bacteriophages with induced virulence or their combinations with the composition containing target additives able to form a stable foam structure, is characterised by porous structure and fragility, has a relative disintegration shrinkage at least 10 %, equivalent pore diameter 10-110 mcm at particle size no more than 100 mcm and a resting angle less than 50° in the following proportions in 1.0 g of the composition: Bifidobacterium bacteria 106-1010 CFU and/or Lactobacillus bacteria 106-1010 CFU, and/or species-specific virulent bacteriophages of Appelman's lytic activity at least 10-4 with respect to test strains and bacterial isolates recovered from a human body, and/or species-specific bacteriophages of induced virulence of Appelman's lytic activity at least 10-4 with respect to test strains and bacterial isolates recovered from a human body, target additives - the rest. |
|
 |
Method for prevention of cattle technological stresses Invention relates to veterinary science. A method involves in the fact that the biological preparation lactoenterol 50 g per a head is introduced in animals before stress exposure. |
|
Using actinomycetes lysate for preparing dermatics for treating acne and method of treating acne Invention refers to dermatology and represents using lysate of strains Actinomyces R/3.88, L/1.89 or their mixtures for preparing dermatics for treating acne, as well as a method for treating acne characterised by the fact that actinomycetes lysate according to cl.1 is applied on skin of a patient in need thereof. |
|
 |
Mean chain length dicarboxylic acid, their derivatives and metabolic disorders Invention refers to medicine and pharmacology and represents using a composition containing sebacic acid and/or its derivatives selected from salts and esters for making a product for oral and enteral introduction which is applicable for: (i) treating or preventing peripheral insulin resistance, impaired glucose tolerance, diabetes, hyperglycemia and related disorders, such as nephropathy, retinopathy, cardiac and cardiovascular diseases (ii) increased glucose clearance and/or insulin responsitivity; (iii) hepatic glucose formation inhibition or (iv) reduced endogenous glucose production. |
 |
Non-infected fresh hen eggs are selected with their further incubating for 9 days. On 5, 6, 7 days hen egg is radiated for 30 s at frequency of modulation 9 Hz and radiation voltage 9 mW with further cooling of eggs for 6-7 days at temperature 2-4°C and homogenisation of eggs. Obtained homogenate is subjected to processing by ultrasound in ultrasonic dispersant. To homogenate, processed with ultrasound, added is mixture, containing 0.1% solution of sodium benzoate and 0.1% of solution of potassium sorbate in equal parts, in weight ratio 1:1 respectively with further ultramicrofiltration through filters with 0.2 mcm diameter, obtaining biologically active substance for embryonic-egg mass. Homogeneous mass is prepared in the following way. Medical gelatin is covered with decoction, containing calendula decoction and chamomile decoction in weight ratio 1:1, keep at temperature 20-25°C for 55-60 minutes with further placement of decoction with gelatin on water bath at temperature 65-70°C until complete dissolusion of gelatin is obtained. Into obtained decoction with gelatin added are amikacin, furacilline, anesthesin, amaranth oil, glycerol and brilliant green with further mixing in homogeniser for 4-5 min obtaining homogeneous mass. To obtained homogeneous mass biologically active substance from embryonic-egg mass is added in specified ratio and mixed in homogeniser for 5-7 min. Obtained mass is poured into special vessels and are placed in thermostat for 3.5-4 hours at temperature 37-39°C with further cooling for 1-2 days until plates solidify in form of plates. |
|
Method of mink coccidiosis treatment and prevention Invention relates to veterinary science. A method involves oral introduction of a therapeutic dosage of Toltrazuril 30 mg/kg to minks for two days or a preventive single dosage, and Subalin 20 mg/head for three days running. |
|
 |
Mucosal induction of antigen tolerance Invention is implemented by using a microorganism expressing an immunomodulatory compound combined with an antigen in the form of a drug, therapeutic foodstuff or nutraceutical for induction of immune tolerance or treatment of an immune response associated disease. Particularly, the invention discloses induction of regulatory T-cells producing Foxp3+ and/or IL-10, and/or TGF-β which are able to suppress undesired immune antigen responses by oral delivery of said antigen combined with a microorganism secreting immunosuppressive cytokine. Described is a method of induction of immune antigen tolerance in an animal and a method of treating the immune response associated disease by mucosal delivery of the antigen combined with the microorganism, expressing the immunomodulatory compound. Also, described is the drug, nutraceutical or therapeutic foodstuff for treatment, prevention and/or relief of the immune response associated disease. |
|
Method of treating patients with ulcerative colitis Invention relates to medicine and is intended for prevention of candidal lesions of digestive tract in treatment of patients with ulcerative colitis (UC), who obtain glucocorticosteroid (GCS) therapy. Therapy with glucocorticosteroids and 5-aminosalicilic acid preparations is carried out. Additionally administered is preparation "Vitaflor", intake per os in dose 1 capsule, covered with intestinally soluble coating, two times per day during entire treatment period. |
|
 |
Saccharomyces exiguous SJP6728AF1 (KCCM-10675P) strain and Saccharomyces exiguous S JP6729AF2 (KCCM-10677P) strain are used to produce bactericidal agents, insecticides, microbial preparations for fermentation of organic wastes, preparations for preventing appearance of or eliminating foul smell of organic wastes, for producing preservatives, feed additives and fermented food products. |
|
In order to prevent and correct central nervous system (CNS) disorders in case of lead intoxication in prenatal and early postpartum period preparation baliz-2 is introduced in doses 0.3 ml per 1 kg of body weight during all pregnancy for 7 days before delivery and for 7 days after delivery. |
|
|
Method to increase breeding efficiency of cows Following components are introduced into cows during calving before heat daily once a day per 100 kg of animal mass - serotonin 2.0 ml 1% aqueous solution intramuscularly, probiotic subtilben 20.0 g included into fodder, dry herb of nettle 50.0 g in composition of fodder. |
|
|
Agent to treat and prevent disbacterial conditions of intestine in birds Agent to treat and prevent disbacterial conditions of intestine in birds contains inulin prepared on milk whey, ferment of live microorganisms Lactobacillus acidophilus, Enterococcus faecium, prepared on skimmed milk, potassium iodide, monobasic calcium phosphate, vitamin E (alpha-tocopherol acetate), vitamin D3 (cholecalciferol), vitamin A (retinol acetate) at the following ratio of components, wt %: inulin 0.5-0.6; milk whey 55.281 -51.979; ferment of live microorganisms Lactobacillus acidophilus, Enterococcus faecium, prepared on skimmed milk 5.5-6.5; potassium iodide 1.25-1.35; monobasic calcium phosphate 37-39; vitamin E 0.45-0.55; vitamin D3 0.0125-0.0135; vitamin A 0.0065-0.0075. |
|
|
General health-improving agent in treating new growths Invention refers to medicine, and concerns a general health-improving agent in treating new growths. Substance of the invention covers avirulent bacteria suspension in a stable, irreversible L-form of strain No. 118-L3 with metabolic products in 1-2 % sodium chloride. |
|
|
Method of treating helminthiases in mammals Invention relates to field of veterinary medicine. Method lies in the following: dehelminthisation of animal, which needs such treatment, is carried out by introduction of antihelminthic of avermectin series. Additionally before and after dehelminthisation therapeutically efficient dose of Roncoleukin is introduced subcutaneously. |
|
 |
Method of treating mycotic infections and preparation for implementation thereof Lytic exoenzyme of Cellulomonas cellulans strain RNCIM AS-870 of molecular weight within 100 to 30 kDa and specific activity 48.3 UN/mg of protein and more is used. A preparation for treating mycotic infections contains lytic exoenzyme of Cellulomonas cellulans strain RNCIM AS-870 of molecular weight within 100 to 30 kDa and specific activity 48.3 UN/mg and more of protein and represents a topical drug. |
 |
Agent for treating gastrointestinal disturbances and method for making thereof Invention refers to medicine, namely to agents for treating gastrointestinal disorders (GID) based on probiotics, and their metabolites. There is offered a preparation containing (wt %): zeolite - 70÷80; soya flour hydrolysate - 15÷25; calcium stearate - 0.5÷1.5; lytic enzymes - 0.05÷3.5; microorganism cell lysate - the rest. The method involves microorganism cultivation, mixing of a metabolite mixture with zeolite and adjuvants, sterilisation and packing of an end product; and the prepared producing microorganism cells are treated with lytic enzymes for 2-10 hours at temperature +20-50°C. If necessary, the composition additionally contains enzymatic preparations to the preset parametres. An agent represents a preparation of broad clinical effectiveness; it is recommended in treatment regimens for the patients suffering from intestinal dysbacteriosis of various geneses. |
 |
Prevention and treatment of cryptosporidiosis in calves Invention belongs to veterinary medicine. Method consists of ingestion of Vetom 4 once a day with colostral milk, milk or warm boiled water during morning feeding in the rate 75-100 mg/kg of body mass. |
 |
Impenetrable for water steam member-carrier for use in adsorbing product Described is adsorbing product, such as sanitary napkin, panty liners, protective means at incontinence, diaper, including adsorbing structure (4) with first and second sides, humidity-sensible additive (8) such as bacterial composition and member-carrier (10). Member-carrier (10) including first and second impenetrable for water steam layer (12, 13) of fabric, at that layers of fabric are tightened with compression (11) with formation of impenetrable for water steam volume between them (9), withholding humidity-sensible additive (8). Member-carrier (10) is situated on the first or second side of adsorbing structure (4). |
 |
Compositions and methods of treating neurological disturbances Therapeutically effective amount of a proteosome composition containing a preparation of outer membrane protein of gram-negative bacteria. |
|
Method for prevention of respiratory disease and improving fertility in young deers An antibacterial agent, probiotic "Sachabactisubtyl" from strains "Bacillus subtilis "ТНП-3-ДЕП"" and "Bacillus subtilis "ТНП-5-ДЕП"", adsorbed on zeolite of Honguru deposit. |
|
 |
Described is adsorbing product, such as sanitary towel, everyday towel, tampon, diaper, diaper in form of underpants, protective means for incontinence for adult people, provided with at least one capsule (8), containing bacterial composition (11) in lipid phase (12), which preferably contains, at least, one strain of bacteria producing lactic acid. At least one part of capsule has minimal transversal size (a), equal to at least 2 mm. Capsule (8) preferably includes core (9), which contains bacterial composition (11) in lipid phase (12), and coating (10), preventing environment impact on core during transportation and storage. |
 |
Method for treatment of gastrointestinal diseases in calves Method includes bottle-feeding of EM-preparation "Baykal EM-1" to calves in mixture with infusion of herbal tea in ratio of 1:1. At the same time herbal tea contains the following components (per 100 ml of water): 0.5 g of touch-and-heal herb, 0.5 g of meadowsweet herb, 0.35 g of thousand-leaf herb, 0.35 g of stinging nettle, 0.2 g of Bergenia crassifolia rhizome, 0.2 of roots and rhizome of cowberry and 0.15 g of Scotch pine needles. Mixture is bottle-fed according to the following scheme: 1 day - twice in doses of 30 ml and 50 ml; 2 day - thrice in dose of 100 ml; further - five times a day in dose of 100 ml until clinical recovery. |
 |
There is described adsorbent product, such as a hygienic towel, a daily liner, a tampon, a diaper, a diaper panties, a protective aid for incontinence in adults, containing a bacterial composition (8) in lipid phase (9), and the specified bacterial composition contains at least one strain of bacteria producing lactic acid. The lipid phase (9) containing the specified bacterial composition (8), is applied on a carrier element (10) or therein. The carrier element, at least before the product is applied, is impenetrable to the lipid phase. The carrier element is located on the side of the adsorbent structure (4) turned to the user so that to prevent considerable transmission of the lipid phase in the adsorbent structure. |
|
Method of preparing probiotic drug Method involves preparation of a stock culture through combined growth of lactic acid bacteria Enterococcus faecium B 3491, Lactobacillus plantarum B 3242, Bifidobacterium bifidum AC 1247 under submerged cultivation conditions, taken in ratio of 1:1:1 until achieving bio-titre of each bacterium of not less than 5·108 CFU/ml. Growth is carried out in a liquid medium which is a mixture of cow milk and water in ratio of 1:1. A mixture of extraction cakes-aromatic herbs is prepared from cumin seeds, coriander seeds and parsley herbs after CO2 extraction with the following ratio of components, wt %: extraction cake of cumin seeds 20-40, extraction cake of coriander seeds 30-50, extraction cake of parsley 30. The obtained mixture of extraction cakes is inoculated with the stock culture in ratio of 1:1 and incubated at 35-40°C for 4-6 days to obtain not less than 5·109 CFU/g in a semihumid preparation. The obtained semihumid preparation is mixed with the obtained mixture of extraction cakes until attaining moisture content of 8-12% in the ready preparation and a bio-titre of each microorganism of not less than 5·108 CFU/g. |
|
|
Microbiological method for preparation of 7α-hydroxyandrostenes Method of selective preparation of 7α-hydroxyandrostens with the help of floccus, includes transformation of Δ5 -androstenes with the help of mycelium Curvularia lunata VKPM F-981 separated and washed from medium. At the same time substrate is used in the form of microchips, or in the complex with cyclodextrins. |
|
 |
Method of treating gastrointestinal diseases in calves Method includes internal application of medication "EM-kurunga" in form of kurunga metheglin in mixture with infusion of phytopreparation, which includes in terms of per 300 ml of water 1.0 g of St. John's wort herb, 1.0 g of honeysweet herb, 0.7 g of sanguinary herb, 0.7 g of stinging nettle herb, 0.4 g of leather bergenia herb rhizomes, 0.4 g of roots and rhizomes of comarum palustre and 0.3 g of common pine needles, 300 ml of water, in ratio 1:1. Mixture is kept to mature at temperature 18-20°C during 24 hours and applied internally in accordance with the following scheme: 1 day - twice in doses 30 ml and 50 ml; 2 day - three times in dose 100 ml; in following days - five times in dose 100 ml to clinical recovery. |
|
Method for making dry synbiotic preparation Mother culture is prepared by consistent cultivation of lactic microorganisms Lactobacillus acidophilus B 3235, Lactobacillus delbrueckii subsp.bulgaricus B 5788, Bifidobacterium longum AC 1249, Bifidobacterium adolescentis AC 1244, taken in equal proportion on the nutrient medium consisting of the following components, wt %: cow's milk 50, glucose 5-15, lactose 5-15, agar 3-4, water - the rest. Solid state fermentation of the mother culture is carried out on sterilised amaranth flour in the ratio 1:1 at 35-40°C during 4-6 days to produce a semihumid preparation of 2·109 CFU/g and more. The latter is mixed with the sterilised amaranth flour to ensure humidity of the finished preparation 8-12% and of the biotitre 2-108 CFU/g and more. |
|
|
Therapy of otoacariasis in fur-bearing animals Invention concerns veterinary science and can be used in fur breeding in case of development of otoacariasis. The therapy involves single subcutaneous introduction of preparation Bovinet in a dose 0.2 mg/kg of animal's weight. |
|
 |
Medicine for treatment of gastrointestinal tract diseases in chickens Medicine contains symbiotic system of strains of lactic acid bacteria Lactobacillus acidophilus D-75 and D-76 of medicine "Vitaflor", enrofloxacin and twin-80 with following ingredients ratio (% wt) symbiotic microorganisms of "Vitaflor" medicine - 10-20; enrofloxacin - 75-85; twin-80 - 1-2. |
|
Method of treatment of purulo-necrotic wounds in necrobacillosis in reindeers Method consists in using a substance consisting of 9 parts of biologically active hydrolyzate of velvet antlers and 1 part of bacterium Bacillus subtilis "ТНП-3-ДЕП" strain suspension, containing 10 billions of microbial cells per 1 ml. |
|
 |
Antibacterial and necrolytic local lisoamidase pharmaceutical composition Invention is applied for treatment of purulent wounds and burns, pyoinflammatory dermatopathies, and for acceleration of healing and improvement of wound healing conditions. The composition possesses antibacterial and necrolytic action; it contains an active complex of bacteriolytic and proteolytic enzymes - Lisoamidase, and a base for soft formulation of the composition. The base contains a thermally stable perfluororganic compound emulsion with gas-transport properties and mixed hydrophilic substances specified as follows: proxanol-268, polyethylene oxides, propylene glycol, dimexide, hyaluronic acid or sodium hyaluronate, sorbite, glycerine, aerosil. Besides, the composition can contain at least one desired additive chosen from: anaesthetic (Chinoxycaine, Trimecaine, Pyromecaine, Lidocaine or mixed), a reparative process stimulator (methyluracil, acetamine, ethadene, calcium pantothenate, Solcoseryl or mixed) or mixed. The composition is made in the form of ointment or gel, rectal suppositories or capsules. |
|
Method of cows endometritis prevention Method consists that microbial preparation is probiotic Sakhabactisubtil representing suspended strains of bacteria Bacillus subtilis TNP-3-DEP and Bacillus subtilis TNP-3-DEP half-and-half. Probiotic Sakhabactisubtil is introduced in dosage 30 ml within 10 days of every month, three months prior to calving. |
|
 |
Biologically active preparation represents a liquid allocated of biological raw materials a destruction of cellular structure processed by constant and low-frequency variable or impulsive field, from information structures of initial raw materials, with characteristic frequencies of spectra of excitation inherent in last and absorption in an ultra-violet and dark blue part of a spectrum of 190-440 nanometers, and also versions of way of its obtaining. The way by the first version includes raw materials freezing, thawing and fast sublimation at temperature 30-45°C with the subsequent condensation and condensate processing by the combined constant field in a range of magnetic induction 0.01-100 mT and a low-frequency variable or impulsive field in a range of a magnetic induction 0.01-100 mT then separate the firm rest with obtaining of a target product in the form of condensate. The way by the second version includes raw materials drying under vacuum at warming with simultaneous processing by the combined constant field in a range of a magnetic induction 0.01-100 mT, and low-frequency variable or impulsive field in a range of a magnetic induction 0.01-100 mT, condensation on walls of the closed volume which temperature support within dew-point temperature then separate the solid residue with obtaining of a target product in the form of condensate. |
Another patent 2513517.